Paper Details

  1. Home
  2. Paper Details

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

Author: AndreThierry, BelleraCarine, BertucciFrançois, BlayJean-Yves, BompasEmmanuelle, CecchiFabiola, ChevreauChristine, CrombeAmandine, HembroughTodd, IsambertNicolas, ItalianoAntoine, KindMichèle, Le CesneAxel, Le LoarerFrançois, LebbeCeleste, LucchesiCarlo, PenelNicolas, Piperno-NeumannSophie, PulidoMarina, Ray-CoquardIsabelle, SaadaEsma, SouliePatrick, SweetStephen, ToulmondeMaud

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Desmoid tumors are locally aggressive and cause significant health problems. There are no approved systemic treatments, and methotrexate-vinblastine is the only chemotherapy studied so far. This study aims to investigate the antitumor activity and safety of pazopanib, a targeted therapy, or combination chemotherapy for progressive desmoid tumors.
Paper Details　
Original Abstract of the Article :
Desmoid tumours are locally aggressive tumours associated with substantial morbidity. No systemic treatments are approved for this disease, with methotrexate-vinblastine the only chemotherapy regimen assessed in a clinical trial setting to date. VEGF overexpression is a common feature in aggressive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(19)30276-1

データ提供：米国国立医学図書館（NLM）

Desmoid Tumors: A New Frontier in Targeted Therapy

Desmoid tumors are a rare and aggressive type of tumor that can cause significant health problems. These tumors are known for their ability to grow and spread, making them difficult to treat. This study investigates the potential of two different treatment approaches for desmoid tumors: pazopanib, a targeted therapy that blocks the growth of blood vessels supplying the tumor, and combination chemotherapy using methotrexate and vinblastine. The researchers conducted a phase 2 study involving patients with progressive desmoid tumors, comparing the efficacy and safety of these two treatment approaches. The study aimed to assess the antitumor activity of both therapies and their safety profiles.

A New Oasis in the Desert of Desmoid Tumors

The study findings are encouraging, suggesting that both targeted therapy and combination chemotherapy may offer potential benefits for patients with desmoid tumors. However, it's important to note that this was a phase 2 study, and further research is needed to confirm these results and determine the optimal treatment approach for different patients.

Navigating the Complexities of Desmoid Tumors

Desmoid tumors pose a unique challenge due to their aggressive nature. This study highlights the potential of both targeted therapy and combination chemotherapy in combating these tumors. The research suggests a need for further investigation into the effectiveness and safety of these treatment approaches for different patient populations.

Dr.Camel's Conclusion

This research provides a promising glimpse into the potential of targeted therapy and combination chemotherapy in treating desmoid tumors. While further research is needed to fully understand the best treatment strategies, the study findings offer hope for patients facing this challenging disease. This exploration into new therapeutic approaches underscores the ongoing effort to find effective treatments for rare and aggressive cancers.

Date :
  1. Date Completed 2020-06-29
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31331699

DOI: Digital Object Identifier

10.1016/S1470-2045(19)30276-1

Related Literature

Article Analysis
・Side Effects of vinblastine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.